N-desethyl Etonitazene
- CAS No.
- 2732926-26-8
- Chemical Name:
- N-desethyl Etonitazene
- Synonyms
- N-DESETHYL-ETONITAZ;N-desethyl Etonitazene;2-[(4-ethoxyphenyl)methyl]-N-ethyl-5-nitro-;1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)methyl]-N-ethyl-5-nitro-
- CBNumber:
- CB710746911
- Molecular Formula:
- C20H24N4O3
- Molecular Weight:
- 368.43
- MDL Number:
- MOL File:
- 2732926-26-8.mol
| Boiling point | 583.2±45.0 °C(Predicted) |
|---|---|
| Density | 1.23±0.1 g/cm3(Predicted) |
| solubility | DMF: 25 mg/ml; DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml; DMSO: 20 mg/ml; Ethanol: 10 mg/ml |
| form | A crystalline solid |
| pka | 9.84±0.19(Predicted) |
| InChI | InChI=1S/C20H24N4O3/c1-3-21-11-12-23-19-10-7-16(24(25)26)14-18(19)22-20(23)13-15-5-8-17(9-6-15)27-4-2/h5-10,14,21H,3-4,11-13H2,1-2H3 |
| InChIKey | RESPFUMJVJRUMB-UHFFFAOYSA-N |
| SMILES | C1(CC2=CC=C(OCC)C=C2)N(CCNCC)C2=CC=C([N+]([O-])=O)C=C2N=1 |
| FDA UNII | QRN9B8Z285 |
N-desethyl Etonitazene Chemical Properties,Uses,Production
Description
N-desethyl Etonitazene (Des-Eto) is an opioid analgesic, a metabolite of ethnonitro and a benzimidazole derivative. It has a good analgesic, and hypnotic effect, and can cause euphoria. This compound has a high opioid activity equal to etonidazine, which can only be compared with strong opioid drugs. High doses of the drug can cause side effects, such as respiratory depression up to death.
Chemical Properties
Yellow Powder.
Uses
N-desethyl Etonitazene is an analytical reference standard that is structurally similar to known opioids.It is intended for research and forensic applications.
Definition
N-desethyl Etonitazene is not prohibited for scientific and research purposes in many countries of the world, including EU countries, but this drug may be subject to the law on analogues of etonitazene, as, for example, in the United States.
References
1. Isotonitazene quantitation and metabolite discovery in authentic forensic casework. DOI:10.1093/jat/bkaa016
2. Synthesis, chemical characterization, and μ-opioid receptor activity assessment of the emerging group of "nitazene" 2-benzylbenzimidazole synthetic opioids DOI:10.22541/AU.160520665.59016513/V2